FINNENCE ▪ THE WIRE FILE
THE WIRE · № 59158
News■ Mixed
Lundbeck announces headline results from Phase IV THRIVE trial evaluating VYEPTI® (eptinezumab) following inadequate response to prior CGRP-targeting preventive therapy
KINDNews
DIRECTION■ Mixed
SOURCES2
ENTITIES1
STORY SIZESTANDALONE
FIRST SEEN2026-10-01 06:17 UTC
LAST UPDATE2026-10-01 06:22 UTC
STATEactive
01 THE MACHINE READ
WHY IT MATTERS.
Positive Phase IV data can support label expansion and prescribing after prior CGRP failure.
Adds prospective evidence for post-CGRP migraine use
CATALYST TO WATCH
Regulatory or guideline updates citing THRIVE
MAIN RISK
Small trial, no pricing or revenue detail given
FULL DISPATCH
Primary endpoint analysis of the clinical Phase IV THRIVE trial showed that 60% of participants reported being 'much improved' or 'very much improved' following treatment with eptinezumab Results provide prospective clinical data on the use of eptinezumab in adults with migraine following...
02 THE STORY SO FAR
THE RECORD, IN ORDER.
STANDALONE ITEM — NOT YET FOLDED INTO A DEVELOPING STORY.
03 WHO'S INVOLVED
ENTITIES ON FILE.
AFFECTEDHealthcare
04 RECEIPTS
THE SOURCE RECORD.
2 SOURCES CONFIRMED05 PROPAGATION
WHAT THIS TOUCHES.
→CORRELATIONshares Healthcare
After scrapping merger, AriBio Group bets on AR1001 and non-pharma cash to fund dementia push2026-10-01 04:58 UTC
After scrapping merger, AriBio Group bets on AR1001 and non-pharma cash to fund dementia push2026-10-01 04:58 UTC
→CORRELATIONshares Healthcare
Three Companies Control 80% of the Prescription Market. AlignRx Built a Public Benefit LLC to Push Back, and Tells the Story on "All Access with Andy Garcia"2026-10-01 07:00 UTC
Three Companies Control 80% of the Prescription Market. AlignRx Built a Public Benefit LLC to Push Back, and Tells the Story on "All Access with Andy Garcia"2026-10-01 07:00 UTC
→CORRELATIONshares Healthcare
Robots Can Do It, Oura Cancels IPO, and Heidi Redux2026-10-01 07:05 UTC
Robots Can Do It, Oura Cancels IPO, and Heidi Redux2026-10-01 07:05 UTC
→CORRELATIONshares Healthcare
SciBase announces outcome of rights issue of shares2026-10-01 07:17 UTC
SciBase announces outcome of rights issue of shares2026-10-01 07:17 UTC
←CORRELATIONshares Healthcare
Merger Dominoes Fall as HealthPartners and Essentia Combine2026-09-30 14:11 UTC
Merger Dominoes Fall as HealthPartners and Essentia Combine2026-09-30 14:11 UTC
←CORRELATIONshares Healthcare
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study2026-09-30 22:00 UTC
Lilly's oral GLP-1, Foundayo (orforglipron), demonstrated cardiovascular safety alongside sustained A1C reduction and weight loss in its largest and longest type 2 diabetes study2026-09-30 22:00 UTC
KEEP READING THE MACHINE
Summaries are generated and may contain errors — every claim links its sources.